Consistent with our recent reports in liver cancer and breast cancer (3, 5), increased ZHX3 expression has been found to be correlated with a favorable OS in patients with lung cancer and may be of value to predict the outcomes of patients with early-stage disease. Here, ZHX3 is linked to lung carcinoma.